Exparel vs Exparel Plus ACB in TKAs
Two-arm, Double-blind Randomized Study Comparing Exparel and Exparel Plus an Adductor Canal Block in Total Knee Arthroplasty
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
- Steadman Hawkins Clinic of the Carolinas - Greenville Health System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, aged 18 to 80 years at the time of surgery.
- Willing and able to give voluntary informed consent to participate in this investigation.
- Candidate for total knee arthroplasty.
- BMI < 35.
Exclusion Criteria:
- Subject has had previous arthroplasty or fracture procedure(s) on the operative knee.
- Creatine level ≥ 1.5
- Pre-existing gait disturbance or neuropathy.
- Allergy to local anesthetics.
- Inflammatory arthropathies.
- Female patient who is pregnant or nursing.
- Chronic use of narcotics
- Any other reason (in the judgment of the investigator).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Exparel plus Adductor Canal Block
Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine
|
Other Names:
|
|
Placebo Comparator: Exparel plus Placebo Block
Adductor canal block with 20 cc saline
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain as assessed by Visual Analog Scale (VAS)
Time Frame: 12 Months
|
Pain, as assessed by Visual Analog Scale (VAS)
|
12 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Function as assessed by Knee Society Score (KSS) and EQ-5D
Time Frame: 12 Months
|
Function, as assessed by Knee Society Score (KSS) and EQ-5D
|
12 Months
|
|
Opioid consumption as assessed by dosage and frequency of narcotic usage
Time Frame: 30 hours
|
Opioid consumption, as assessed by dosage and frequency of narcotic usage
|
30 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brayton Shirley, Steadman Hawkins Clinic of the Carolinas - Greenville Health System
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Anesthetics, Local
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Sympatholytics
- Vasoconstrictor Agents
- Mydriatics
- Bupivacaine
- Ropivacaine
- Epinephrine
- Clonidine
Other Study ID Numbers
Other Study ID Numbers
- Pro00034356
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.